The company
Cytokinetics, Incorporated
CYTK · Nasdaq
CYTK stood above a rising 150-day average in 47 of the last 52 weekly readings, and has been out of that trend for the last 5 weeks. It is 14.2% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 5
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $93.8M
- Officials’ trades on record
- 5
- Institutions holding
- 451 (+38)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 47 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
5 disclosed lines: House 5, Senate 0, executive 0; 2 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31 | bought | $1k–$15k | 29 Sep 2026filed 12 Oct 2026 |
| Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31 | bought | $1k–$15k | 30 Jun 2026filed 2 Jul 2026 |
| Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31 | bought | $1k–$15k | 9 Oct 2025filed 18 Nov 2025 |
| Lisa C. McClain House: U.S. House ClerkMI09 | soldspouse | $1k–$15k | 17 Jun 2025filed 13 Aug 2025 |
| Lisa C. McClain House: U.S. House ClerkMI09 | boughtspouse | $1k–$15k | 11 Jun 2025filed 13 Aug 2025 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Robert I. BlumPresident & CEO | sold | 7,500at $62.88 | 12 Oct 2026filed 13 Oct 2026 |
| Fady Ibraham MalikEVP Research & Development | sold | 3,500at $61.38 | 6 Oct 2026filed 6 Oct 2026 |
| Robert I. BlumPresident & CEO | sold | 7,500at $65.46 | 28 Sep 2026filed 28 Sep 2026 |
| Fady Ibraham MalikEVP Research & Development | sold | 3,500at $68.29 | 22 Sep 2026filed 22 Sep 2026 |
| Robert I. BlumPresident & CEO | sold | 97,926at $69.33 | 15 Sep 2026filed 15 Sep 2026 |
| Robert E. LandryDirector | sold | 1,000at $72.13 | 15 Sep 2026filed 15 Sep 2026 |
| Robert I. BlumPresident & CEO | sold | 7,500at $73.44 | 14 Sep 2026filed 15 Sep 2026 |
| Robert E. LandryDirector | sold | 1,000at $74.66 | 11 Sep 2026filed 11 Sep 2026 |
| Fady Ibraham MalikEVP Research & Development | sold | 3,500at $75.46 | 8 Sep 2026filed 8 Sep 2026 |
| B. Lynne ParshallDirector | sold | 5,000at $71.48 | 1 Sep 2026filed 1 Sep 2026 |
| Robert I. BlumPresident & CEO | sold | 7,500at $70.24 | 31 Aug 2026filed 31 Aug 2026 |
| Andrew CallosEVP, Chief Commercial Officer | sold | 10,000at $70.24 | 31 Aug 2026filed 31 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| BlackRock, Inc.added · filed 7 Aug 2026 | 20,094,362$1.7B | +3,546,351+21.4% |
| WELLINGTON MANAGEMENT GROUP LLPreduced · filed 14 Aug 2026 | 6,931,770$590.5M | -1,077,719−13.5% |
| VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026 | 6,711,799$571.8M | +868,017+14.9% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 6,494,233$553.2M | +749,040+13.0% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 6,117,515$521.2M | +628,881+11.5% |
| FMR LLCreduced · filed 13 Aug 2026 | 5,031,782$428.7M | -5,691,358−53.1% |
| Avoro Capital Advisors LLCadded · filed 14 Aug 2026 | 4,999,999$425.9M | +1,666,666+50.0% |
| BANK OF AMERICA CORPadded · filed 14 Aug 2026 | 4,635,709$394.9M | +1,510,273+48.3% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 3,712,501$316.3M | +497,086+15.5% |
| RTW INVESTMENTS, LPadded · filed 14 Aug 2026 | 2,862,003$243.8M | +140,845+5.2% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.